Novo Nordisk A/S $NVO Shares Purchased by Beverly Hills Private Wealth LLC

Beverly Hills Private Wealth LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 3.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 44,882 shares of the company’s stock after acquiring an additional 1,679 shares during the quarter. Beverly Hills Private Wealth LLC’s holdings in Novo Nordisk A/S were worth $3,098,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in NVO. Copeland Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. purchased a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $27,000. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $30,000. Disciplina Capital Management LLC increased its stake in Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the period. Finally, Dagco Inc. purchased a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $35,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 3.0%

Shares of NYSE:NVO opened at $54.41 on Monday. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $118.26. The company’s 50 day moving average is $56.24 and its two-hundred day moving average is $62.69. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The company has a market cap of $242.93 billion, a PE ratio of 14.95, a P/E/G ratio of 2.50 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is presently 22.53%.

Wall Street Analyst Weigh In

NVO has been the topic of several recent research reports. BMO Capital Markets reaffirmed a “market perform” rating and set a $55.00 target price (up from $50.00) on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. TD Cowen cut their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 19th. Finally, UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $76.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.